Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by TedOwenson Feb 21, 2014 12:15pm
224 Views
Post# 22235204

RE:RE:RE:RE:RE:RE:RE:BRD and the 12 Month PPS High

RE:RE:RE:RE:RE:RE:RE:BRD and the 12 Month PPS HighThere are several parties not in favor of this deal so don't count on the deal being a slam dunk as is being inferred through ambiguous headlines which when read more closely, clearly reference a weaker position for Primero and ultimately, Brigus shareholders...................The upside over the coming 4-6 months is multiples higher with Brigus as a standalone exploration and development entity over that which Primero would enable.............Big discovery news is pending and it will be much more likely that Brigus will be a 4-6 dollar stock over a Primero scenario being a 24 dollar stock given the valuation increase ratio returns to lower price shareholders than the higher one................Primero is a "gold equivalent" valuation on the books and as such, will not be in the same category as Brigus would be when gold prices return to higher levels.
Bullboard Posts